1 It was the aim of our study to investigate the eects of the sulphonylurea glibenclamide on voltage dependent potassium currents in human atrial myocytes. 2 The drug blocked a fraction of the quasi steady state current (ramp response) which was activated positive to 720 mV, was sensitive to 4-aminopyridine (500 mM) and was dierent from the ATP dependent potassium current I K(ATP) . 3 Glibenclamide dose dependently inhibited both, the peak as well as the late current elicited by step depolarization positive to 720 mV. The IC 50 for reduction in charge area of total outward current was 76 mM. 4 The double-exponential inactivation time-course of the total outward current was accelerated in the presence of glibenclamide with a t fast of 12.7+1.5 ms and a t slow of 213+25 ms in control and 5.8+1.9 ms (P50.001) and 101+20 ms (P50.05) under glibenclamide (100 mM). 5 Our data suggest, that both repolarizing currents in human atrial myocytes, the transient outward current (I to1 ) and the ultrarapid delayed recti®er current (I Kur ) were inhibited by glibenclamide. 6 In human ventricular myocytes glibenclamide inhibited I to1 without aecting the late current. 7 Our data suggest that glibenclamide inhibits human voltage dependent cardiac potassium currents at concentrations above 10 mM.
Introduction
The sulphonylurea glibenclamide (glyburide) is commonly used for treatment of non-insulin-dependent diabetes mellitus (NIDDM). The bene®cial eect of glibenclamide involves the inhibition of ATP sensitive potassium channels (I K(ATP) -channels) in pancreatic b-cells leading to the release of insulin (Ashford, 1993) . I K(ATP) -channels are also present in other tissues like the myocardium (Noma, 1983) where glibenclamide exerts a potent inhibitory eect (Findlay, 1992) .
The role of glibenclamide in the incidence of arrhythmias and mortality, especially in myocardial ischemia is a matter of debate (for review see Schotborgh & Wilde, 1997) . Beside the use in NIDDM patients glibenclamide is a frequently used tool in cardiovascular research whereby concentrations of up to 100 mM are often used for studying I K(ATP) (for review see Wilde & Janse, 1994 , Schotborgh & Wilde, 1997 . However, at these concentrations glibenclamide may also aect other membrane currents than I K(ATP) and may also aect the metabolism of the heart (Schotborgh & Wilde, 1997) . Suggested as a selective I K(ATP) -blocker glibenclamide is also frequently used in models of ischaemic preconditioning tò prove' a contribution of I K(ATP) in the preconditioning eect (Tomai et al., 1994; Speechly-Dick et al., 1995; Cleveland et al., 1997) .
We investigated the interaction of glibenclamide with voltage dependent outward currents in isolated human atrial and ventricular myocytes by using the patch clamp technique in the whole cell recording mode at a bath temperature of 36 ± 378C. We present evidence that glibenclamide inhibits both repolarizing currents, the transient outward current (I to1 ) and the ultrarapid delayed recti®er current (I Kur ). To our knowledge this is the ®rst report describing glibenclamide eects on human voltage dependent cardiac K + currents.
Methods

Myocyte isolation
Human atrial myocytes were isolated from right atrial appendages which were obtained during open heart surgery. Human ventricular myocytes were isolated from the subepicardium of the left ventricle of explanted hearts. The use of human tissue was approved by the ethical committee of the University of Graz and the study conforms to the standards set by the declaration of Helsinki. Myocyte isolation was performed by the combined use of enzymes (trypsin, collagenase) in a tissue dissociation vessel as described previously . The isolated myocytes were stored in a cell culture medium Sigma) , supplemented with 50 mg ml 71 penicillin and 50 IU ml 71 streptomycin and were kept in an incubator at 378C. Experiments were performed 3 ± 8 h after cell isolation.
Electrophysiological recordings
The isolated myocytes were placed in an experimental chamber mounted on the stage of an inverted microscope (Axiovert, Zeiss, Oberkochen, Germany) and were superfused with extracellular saline (composition in mM: NaCl 137, KCl 5.4, CaCl 2 0.1, MgCl 2 1.1, CdCl 2 0.1, NaHCO 3 0.4, HEPES/Na + 10, D(+)-glucose 5.6, adjusted to a pH of 7.4 with NaOH) at a temperature of 36 ± 378C and a¯ow rate of *3 ml min
71
. A low external calcium concentration in combination with CdCl 2 (Schaer et al., 1998) was used to suppress calcium currents and calcium activated transient outward currents. Membrane currents were recorded as described previously (Schaer et al., 1998) Transmembrane currents were recorded either at a holding potential of 740 mV, in response to voltage clamp ramps from 7100 to +60 mV (0.08 V s 71 ) or by depolarizing clamp steps (740 to +60 mV in steps of 10 mV, 300 ms) from a holding potential of 780 mV which were preceded by a 50 ms prepulse to 740 mV in order to inactivate I Na . In atrial myocytes the inactivation time course of the total outward current could be described by two exponential functions:
slow A ss where I total was the total outward current, A fast and t fast were the amplitude and time constant of the fast inactivation phase, A slow and t slow were the amplitude and time constant of the slow inactivation phase and A ss was the amplitude of the steady state current. The amplitude of the peak outward current and the late current were determined relative to the zero current level.
To study the concentration dependent inhibition of total outward current the reduction in charge movement was calculated. The integral (0 ± 300 ms) of the inactivation function of the total outward current (determined by the amplitudes and time constants derived from the ®tting procedure) was used as a measure of charge movement.
In human ventricular myocytes I to1 was measured as the dierence between the peak of the outward current and the current at the end of the clamp pulse.
Statistics
All data are presented as means+s.e.mean, statistical signi®cance was tested by Student's t-test for paired data. Values of P50.05 were regarded as signi®cant.
Drugs
Glibenclamide and cromakalim stock solutions were prepared in DMSO and further diluted to the desired concentration. The DMSO concentration in the extracellular saline did not exceed 0.1%. 4-aminopyridine (4-AP) was added directly to the extracellular solution. All chemicals were purchased from Sigma.
Results
To test for a contribution of the ATP-dependent potassium current I K(ATP) to basal electrical activity, isolated human atrial myocytes were voltage clamped to 740 mV and superfused with the I K(ATP) -blocker glibenclamide (50 mM). A typical experiment is shown in Figure 1 . It can be seen, that the holding current (I hold740 mV ) was not aected by glibenclamide suggesting that I K(ATP) was not active under these conditions. However, when the quasi steady state current was elicited with a voltage ramp (7100 to +60 mV, 0.08 V s 71 ), a clear outward current inhibition by glibenclamide was noted (see Figure 2a) . The glibenclamide sensitive fraction of the ramp response (obtained by digital subtraction) is shown in Figure  2b . The glibenclamide sensitive current activated positive to 720 mV and was outward directed. This current resembled the 4-aminopyridine (4-AP; 500 mM) sensitive current shown in Figure 2c . In the presence of 4-AP (500 mM) glibenclamide failed to inhibit a fraction of the quasi steady state current (Figure 2d) suggesting that glibenclamide and 4-AP aect the same current components. For comparison, I K(ATP) is shown in Figure 2e (current activated by 100 mM cromakalim, obtained by digital subtraction). I K(ATP) reversed at about 785 mV and diered completely from the glibenclamide sensitive current. These experiments led to the conclusion that (1) I K(ATP) does not contribute to basal electrical activity in human atrial myocytes using a pipette ATP concentration of 4.3 mM and (2) glibenclamide blocked an outward current component which was sensitive to 4-AP and was dierent from I K(ATP) .
To further investigate the glibenclamide sensitive outward current, myocytes were depolarized to potentials between 740 and +60 mV (duration 300 ms; at a frequency of 0.5 Hz) from a holding potential of 780 mV. The depolarizing pulses were preceded by a 50 ms step to 740 mV to voltage-inactivate I Na . Figure 3a shows typical outward current traces under control conditions and under the in¯uence of 30 and 100 mM glibenclamide. Both, the peak outward current and the late current (current at the end of the clamp pulse) were concentration dependently reduced by glibenclamide. Furthermore glibenclamide caused an apparent acceleration of the time-course of inactivation of the total outward current. The time-course of inactivation of the total outward current could be described as a doubleexponential function (see Methods) with t fast of 12.7+1.5 ms and a t slow of 213+25 ms in control and 5.8+1.9 ms (P50.001) and 101+20 ms (P50.05) under 100 mM glibenclamide (at +40 mV; n=5). The eect of glibenclamide on the current voltage relationship of peak total outward current is shown in Figure 3b . Since time course of inactivation was apparently accelerated in the presence of glibenclamide we used charge area reduction of total outward current (at +40 mV) as a measure of the concentration dependent inhibition as shown in Figure 3c . These data were ®tted with a Hill function giving an IC 50 of 76.4+6.3 mM and a slope of 71.21+0.13.
In human left ventricular subepicardial myocytes glibenclamide induced a concentration dependent reduction of I to 1 whereas the non-inactivating fraction of the outward current was not aected (Figure 4a,b,c) . At a concentration of 100 mM glibenclamide I to1 was inhibited by 78.2+2.66% (at +40 mV; n=4).
Discussion
To test whether or not the ATP sensitive potassium current (I K(ATP) ) contributes to the basal electrical activity, isolated human atrial myocytes were superfused with glibenclamide, which is thought to act as a selective I K(ATP) -blocker. Using a pipette ATP concentration of 4.3 mM no I K(ATP) -like current was inhibited, suggesting that I K(ATP) was not active under these conditions. This ®nding con®rms observations by HeidbuÈ chel et al. (1990) who have described the lack of spontaneous openings of I K(ATP) -channels in cell-attached patches of human atrial myocytes.
However, recordings of the quasi steady state current (ramp-response) showed that glibenclamide exerts an inhibitory eect on an outward current component (dierent from I K(ATP) ) which activated positive to 720 mV and was sensitive to low concentrations of 4-AP. Two distinct 4-AP-sensitive outward currents which activate positive to 720 mV have been described in human atrial myocytes recently. A transient outward current (I to1 ) which is sensitive to 4-AP in the millimolar range and an ultrarapid delayed recti®er current (I Kur , I so ) which is sensitive to submillimolar concentrations of 4-AP are present in the human atrium (Wang et al., 1993; Amos et al., 1996; Schaer et al., 1998) .
In human atrial myocytes glibenclamide reduced both, the peak of the total outward current as well as the amplitude of the current at the end of the clamp pulse. Half-maximal inhibition of the total outward current (charge area reduction) was achieved with 76 mM glibenclamide which is one order of magnitude higher than for I K(ATP) -block (5 ± 10 mM; see: Schotborgh & Wilde, 1997) . The eect of glibenclamide on individual currents is dicult to estimate since both, I to1 and I Kur show time dependent inactivation (Feng et al., 1998; Schaer et al., 1998) . Thus, I to1 can not be determined as the dierence between the peak and the late current neither can the amplitude of the late current be regarded as a reliable measure of I Kur .
For this reason we have studied the eects of glibenclamide on the total outward current and ®nd indirect evidence for inhibition of both, I to1 and I Kur . Reduction of the late current under glibenclamide suggests block of I Kur . This assumption is further supported by the glibenclamide induced apparent acceleration of the slow inactivation phase which represents inactivation of I Kur (Schaer et al., 1998) . The apparent acceleration of the fast inactivation phase suggests block of I to1 . In ventricular myocytes where I to1 can be studied without an overlaying I Kur (see: Amos et al., 1996) a clear inhibitory action of glibenclamide on I to1 was seen. This supports our assumption of I to1 block in the atrium. However, further studies will be necessary to investigate the eects of glibenclamide on individual currents in human atrial myocytes (I to1 , I Kur ).
In human ventricular myocytes the late current, which is thought to be a non-selective cation current (Amos et al., 1996) , was unaected by glibenclamide.
Besides aecting I K(ATP) , glibenclamide has been shown to inhibit the cyclic AMP activated chloride current (Tominaga et al., 1995; Faivre et al., 1998) , the cystic ®brosis chloride channel (Sheppard & Welsh, 1992) as well as volume-sensitive chloride channels (Sakaguchi et al., 1997; Liu et al., 1998) . In neuroblastoma cells glibenclamide inhibited a voltage gated potassium current which was independent of intracellular ATP and Ca 2+ (Reeve et al., 1992) . At present we are not aware of any report of glibenclamide eects on voltage dependent potassium currents in human cardiomyocytes. However, recently it was shown that glibenclamide inhibits neural and cardiac HERG-channels (Rosati, et al., 1998) with a similar IC 50 (74.8 mM) as reported in the present study for block of human atrial outward current (76.4 mM). Rosati et al. (1998) suggested that glibenclamide block of HERG channels may indicate the linkage of sulphonylurea receptors to HERG channels. Our data do not support this assumption since the apparent acceleration of inactivation may be interpreted as open channel block and suggest a direct action of glibenclamide on I to1 and I Kur .
Whether or not inhibition of I to1 and I Kur play a role in patients on glibenclamide can not be answered yet. However, I to1 (atrium, ventricle) and I Kur (atrium) play a central role for repolarization in the human heart. Thus glibenclamide may cause an action potential lengthening (class III antiarrhythmic eect) in both the atrium and the ventricle. At 10 mM glibenclamide we found 15 ± 20% inhibition of I to1 in human ventricular myocytes. At this concentration of glibenclamide eects on heart rate and QT interval which were not related to inhibition of I K(ATP) have been described in the rat heart (Rees & Curtis, 1995) . Since tedisamil, a potent I to1 blocking drug (Wettwer et al., 1998) , elicited similar eects (Tsuchihashi & Curtis, 1991) , it was speculated that glibenclamide (at 10 mM) may block I to1 (Rees & Curtis, 1995) .
In clinical use, glibenclamide reaches a blood concentration up to 1.5 mM (Schotborgh & Wilde, 1997) , a concentration where the eects on I to1 and I Kur are marginal. Whether glibenclamide may unmask primary or iatrogenic long-QT syndromes as discussed by Rosati et al. (1998) remains speculative although long QT-syndrome in response to antidiabetic therapy with glibenclamide has been reported recently (Ikeda, 1994) .
The I K(ATP) channel is thought to be the end eector of preconditioning (increased tolerance to myocardial ischaemia and reperfusion by preceding transient ischaemic period; Sumeray & Yellon, 1997) . Knowledge of the role of I K(ATP) in experimental preconditioning is mainly based on the fact that glibenclamide abolishes such a preconditioning eect (Tomai et al., 1994; Speechly-Dick et al., 1995; Cleveland et al., 1997) assuming that glibenclamide is a pure I K(ATP) -blocker. However, our data show that at least in human heart, glibenclamide exerts additional K + channel blocking eects. Thus, a concentration of glibenclamide in/or below the mM range are necessary to induce`selective' I K(ATP) inhibition.
It is further notable that structurally diverse substances inhibit human cardiac I to1 and/or I Kur . Inhibition was reported for classical class III antiarrhythmic agents like ambasilide (Koidl et al., 1996) and tedisamil (Wettwer et al., 1998) , the class Ia agent quinidine (Wang et al., 1995; Nenov et al., 1998) , Ic agents like propafenone (Schaer et al., 1995; Gross & Castle, 1998) and¯ecainide (Wang et al., 1995) and other substances like bertosamil (Tessier et al., 1997) , the antihistamine loratadine (Crumb, 1999) , 4-aminopyridine (Gross et al., 1995; Wang et al., 1995; Schaer et al., 1998) and the sulphonylurea glibenclamide as described in this study.
In summary, the present study describes the inhibitory action of glibenclamide on voltage dependent potassium currents (I to1 and I Kur ) in human atrial and ventricular myocytes. Our data indicate that glibenclamide concentrations in or even below the mM range are required for a selective inhibition of I K(ATP) in the human heart. Since inhibition of I to1 and I Kur (as well as I Kr ; Rosati et al., 1998) occurred at concentrations above the glibenclamide plasma levels, these eects are rather unlikely to play a signi®cant role in NIDDM patients. However, it remains to be determined whether glibenclamide may induce iatrogenic long-QT syndrome under certain conditions.
